The purpose of this study is to compare a new medication to an already existing treatment, Neupogen®, which is currently used for the treatment of neutropenia (low white blood cell count).
This is a biosimilar study, which means that the new medication is almost an identical copy of an already approved drug manufactured by a different company. Biosimilar studies help to put medication on the market in generic versions which can make it more affordable for the patient.
Biosimilar medicines play an important role in the health care for Australians. Because most medicines in Australia are subsidised, lower prices allow the government to subsidise more medicines or spend more on other areas of health care. Biosimilar medicines give patients access to more brand options and can reduce the risk of medicine shortages.
The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.
Call us on 1800 243 733 to discuss your eligibility today!